BD Oncomark™ Anti-Human CD79b FITC/Kappa PE/CD19 PerCP-Cy™5.5
Description
CD79b, clone SN8 (3A2-2E7-1F5), is generated from the fusion of NS-1 myeloma cells with spleen cells from BALB/c mice immunized with an antigen prepared from the membrane of B-prolymphocytic leukemia (B-PLL) cells. Anti-Kappa, clone TB28-2, is derived from hybridization of mouse P3-X63-Ag8.653 myeloma cells with cells from CB6 (BC57b x BALB/c) mice immunized with human IgG-κ myeloma protein. CD19, clone SJ25C1, is derived from the hybridization of mouse Sp2/0 cells with spleen cells from BALB/c mice immunized with NALM1 + NALM16 cells. CD79b, clone SN8, reacts with the CD79b protein and the epitope lies on the extra domain of the peptide. CD79b is helpful in delineating signal transduction pathway activated via antibody receptors during different stages of B-cell differentiation. Anti-Kappa is specific for kappa light chains of human immunoglobulins. CD19 (SJ25C1) recognizes a 90-kilodalton (kd) antigen that is present on human B lymphocytes.
Preparation And Storage
Store vials at 2°C–8°C. Conjugated forms should not be frozen. Protect from exposure to light. Each reagent is stable until the expiration date shown on the bottle label when stored as directed.
| Description | Clone | Isotype | EntrezGene ID |
|---|---|---|---|
| N/A | N/A | | IgG1, κ,IgG1, κ,IgG1, κ | N/A |
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
Although not required, these products are manufactured in accordance with Good Manufacturing Practices.